NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • About Patient and Public Involvement
      • Our Work with Patients and the Public
      • Learn More About Our Research
      • Patient Involvement Blog
      • External Links
    • For Patients, Carers and the Public
      • Current Listings for Involvement
      • REGISTER INTEREST
      • Patient and Public Involvement Workshops
    • PPI Resources for Researchers
      • PPI Strategy
      • A Researcher’s Guide to PPI
      • PPI Resources for Researchers
      • PPI Briefing Notes
      • PPI Case Studies
      • PPI Advisory Group
      • PPI Events for Researchers
      • Post a PPI Listing
      • Public Engagement for Researchers
      • Public Engagement Case Studies
  • Training Hub
    • Training Hub
    • Fellowships
    • Funding Opportunities
    • Clinical Researchers and Scientists
    • Nurses, Midwives and Allied Health Professionals
    • Next Generation Leaders Programme
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Antimicrobial Resistance and Modernising Microbiology > Evaluation of LamPORE rapid Covid-19 tests show high levels of diagnostic sensitivity

Evaluation of LamPORE rapid Covid-19 tests show high levels of diagnostic sensitivity

25 September 2020 · Listed under Antimicrobial Resistance and Modernising Microbiology, COVID-19

Scientists from the University of Oxford’s Nuffield Department of Medicine have today published their evaluation of LamPORE, a novel diagnostic platform for detecting SARS-CoV-2 RNA.

The LamPORE test uses standard Oxford Nanopore Technologies flow cells compatible with the desktop GridION device

This technology, which combines loop-mediated isothermal amplification with nanopore sequencing, has the potential to analyse thousands of samples per day on a single instrument.

The full evaluation paper was published on the pre-print server medRxiv.

The collaboration between colleagues at Public Health England Porton Down (PHE), the University of Sheffield, the University of Oxford, including support from the NIHR Oxford Biomedical Research Centre (BRC), evaluated the performance of LamPORE against RT-PCR – the most commonly-used laboratory test for Covid-19.

They used RNA extracted from two types of samples: initially, mock samples formed of saliva from people without infection that had a known quantity of virus added to it; and subsequently nose and throat swabs from real Covid-19 patients collected during routine care at two UK hospitals – Oxford University Hospitals NHS Foundation Trust and Sheffield Teaching Hospitals NHS Foundation Trust.

The positive clinical specimens came mostly from patients with symptomatic infection, and among these LamPORE had a diagnostic sensitivity of 99.1% (i.e. it was positive in 226 of 228 samples positive by RT-PCR). Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6% (i.e. it was negative in 278 of 279 samples negative by RT-PCR). Overall, 1.4% of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducibility of 96.8%.

These results indicate that LamPORE has a similar performance to RT-PCR for the diagnosis of SARS-CoV-2 infection in symptomatic patients.

Prof Derrick Crook

The evaluation as led by Professor Derrick Crook, from the Nuffield Department of Medicine and the NIHR Oxford BRC’s Theme Lead for Antimicrobial Resistance and Modernising Microbiology. He said: “This evaluation shows that LamPORE offers a promising approach to high-throughput testing.”

Prof Helen McShane, Director of the NIHR Oxford BRC, said: “Oxford’s expertise in clinical microbiology and pathogen sequencing has been combined with state-of-the-art sequencing technology from Oxford Nanopore to generate this really important data. This is an excellent example of how NIHR funding to support academic–industrial collaborations can lead to the development of new tools to help us control the SARS-CoV-2 pandemic.”

Dr Steve Pullan, from PHE Porton Down, said: “Our early data indicates LamPORE to be a credible alternative to conventional PCR-based diagnostics, which has the potential to provide further high-throughput testing capacity.”

Dr Cariad Evans, Consultant Virologist at Sheffield Teaching Hospitals NHS Foundation Trust and joint senior author of the published evaluation, said: “We are pleased to have contributed to this important evaluation. These are encouraging early findings and we are proud to have supported Public Health England and our academic partners in this essential Covid-19 research.”

The LamPORE test uses standard Oxford Nanopore Technologies flow cells compatible with the desktop GridION device and palm-sized MinION Mk1C device. It has the potential to be used both for distributed and centralised laboratory Covid-19 testing.

The protocol currently allows up to 96 samples to be analysed on one flow cell, potentially allowing thousands of samples to be analysed per day on a single instrument. The workflow involves a 40-minute amplification, followed by a library preparation and a 60-minute sequencing run, generating results in a comparable time to RT-PCR when starting with extracted RNA.

Using LamPORE for high-throughput testing of tens or hundreds of thousands of samples per day is dependent on a streamlined workflow, including automated sample handling and integration with laboratory information management systems. The scientists conclude that LamPORE on extracted RNA offers a promising method of high throughput SARS-CoV-2 testing. It could be of much broader use if shown to work with extraction-free methods of sample preparation and automated workflows.

← Oxford assay excels in comparison of SARS-CoV-2 antibody tests
New trial on use of anti-TNF drugs to treat Covid-19 in care homes →

News

  • COVID-19 ‘matching service’ increased public involvement in research, HRA finds 20 January 2021
  • Classification system uncovers new information about ovarian cancers 18 January 2021
  • Ancient gene mutation found to cause rare hereditary condition 18 January 2021
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced bimonthly and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2021 NIHR Oxford Biomedical Research Centre

Cookies

This site uses cookies See our data control and privacy page